Respiratory syncytial virus vaccines

An update on those in the immediate pipeline

Susanna Esposito, Giada Di Pietro

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) is among the most common causes of lower respiratory tract infection among infants and the elderly worldwide. Despite its long history, no licensed vaccine is available. Recently, advances in the knowledge of RSV biology and pathology as well as the development of new techniques to generate vaccine candidates have increased the number of promising vaccines. The aim of this review is to analyze RSV characteristics, to consider the history of RSV vaccines and to discuss RSV vaccines currently in development. Among the candidates in clinical trials, nanoparticle and subunit vaccines seem to be the most promising for pregnant women and the elderly, whereas live-attenuated or vector-based vaccines appear to be optimal for the pediatric population.

Original languageEnglish
Pages (from-to)1479-1490
Number of pages12
JournalFuture Microbiology
Volume11
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Viruses
Vaccines
History
Subunit Vaccines
Respiratory Tract Infections
Nanoparticles
Pregnant Women
Clinical Trials
Pediatrics
Pathology
Population

Keywords

  • prevention
  • RSV
  • vaccines

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Respiratory syncytial virus vaccines : An update on those in the immediate pipeline. / Esposito, Susanna; Pietro, Giada Di.

In: Future Microbiology, Vol. 11, No. 11, 01.11.2016, p. 1479-1490.

Research output: Contribution to journalReview article

Esposito, Susanna ; Pietro, Giada Di. / Respiratory syncytial virus vaccines : An update on those in the immediate pipeline. In: Future Microbiology. 2016 ; Vol. 11, No. 11. pp. 1479-1490.
@article{acfd00c079774a40b612ee8733c6ebee,
title = "Respiratory syncytial virus vaccines: An update on those in the immediate pipeline",
abstract = "Respiratory syncytial virus (RSV) is among the most common causes of lower respiratory tract infection among infants and the elderly worldwide. Despite its long history, no licensed vaccine is available. Recently, advances in the knowledge of RSV biology and pathology as well as the development of new techniques to generate vaccine candidates have increased the number of promising vaccines. The aim of this review is to analyze RSV characteristics, to consider the history of RSV vaccines and to discuss RSV vaccines currently in development. Among the candidates in clinical trials, nanoparticle and subunit vaccines seem to be the most promising for pregnant women and the elderly, whereas live-attenuated or vector-based vaccines appear to be optimal for the pediatric population.",
keywords = "prevention, RSV, vaccines",
author = "Susanna Esposito and Pietro, {Giada Di}",
year = "2016",
month = "11",
day = "1",
doi = "10.2217/fmb-2016-0106",
language = "English",
volume = "11",
pages = "1479--1490",
journal = "Future Microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",
number = "11",

}

TY - JOUR

T1 - Respiratory syncytial virus vaccines

T2 - An update on those in the immediate pipeline

AU - Esposito, Susanna

AU - Pietro, Giada Di

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Respiratory syncytial virus (RSV) is among the most common causes of lower respiratory tract infection among infants and the elderly worldwide. Despite its long history, no licensed vaccine is available. Recently, advances in the knowledge of RSV biology and pathology as well as the development of new techniques to generate vaccine candidates have increased the number of promising vaccines. The aim of this review is to analyze RSV characteristics, to consider the history of RSV vaccines and to discuss RSV vaccines currently in development. Among the candidates in clinical trials, nanoparticle and subunit vaccines seem to be the most promising for pregnant women and the elderly, whereas live-attenuated or vector-based vaccines appear to be optimal for the pediatric population.

AB - Respiratory syncytial virus (RSV) is among the most common causes of lower respiratory tract infection among infants and the elderly worldwide. Despite its long history, no licensed vaccine is available. Recently, advances in the knowledge of RSV biology and pathology as well as the development of new techniques to generate vaccine candidates have increased the number of promising vaccines. The aim of this review is to analyze RSV characteristics, to consider the history of RSV vaccines and to discuss RSV vaccines currently in development. Among the candidates in clinical trials, nanoparticle and subunit vaccines seem to be the most promising for pregnant women and the elderly, whereas live-attenuated or vector-based vaccines appear to be optimal for the pediatric population.

KW - prevention

KW - RSV

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=84994074992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994074992&partnerID=8YFLogxK

U2 - 10.2217/fmb-2016-0106

DO - 10.2217/fmb-2016-0106

M3 - Review article

VL - 11

SP - 1479

EP - 1490

JO - Future Microbiology

JF - Future Microbiology

SN - 1746-0913

IS - 11

ER -